Worth reading
44Recurring
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Improvement
Direction inferred from the company’s description.Scale
162.9
Year-on-year change in operating profit (%)Wording
Conditional
How definitive the wording is.Results for this period
First quarter1 April 2026 to 30 June 2026ConsolidatedJapanese GAAPNet Sales3,287¥ millionYear on year +27.1%Progress 25.1%
Operating profit277¥ millionYear on year +162.9%Progress 30.6%
Ordinary income263¥ millionYear on year +173.3%Progress 31.2%
Net income attributable to owners of the parent176¥ millionYear on year +176.9%Progress 27.9%
The width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
Net income per share¥24.82
Financial position at period-end
Total assets8,669¥ million
of which net assets 2,765 ¥ millionEquity ratio 31.9%vs. prior year-end -1.0pt
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Segment revenueHome-visit pharmacy business ¥2,298,441 thousand (YoY +24.5%), Kirari Prime Business ¥310,277 thousand (YoY +19.6%), Primary Care Home business ¥678,480 thousand (YoY +41.2%), Other businesses ¥111 thousand (YoY -40.2%)
Segment profitHome-visit pharmacy business ¥179,687 thousand (YoY +13.7%), Kirari Prime Business ¥182,981 thousand (YoY +37.8%), Primary Care Home business ¥69,321 thousand, Other businesses ¥-7,226 thousand
Outlook and shareholder returns
Full-year earnings forecast
Net Sales¥13,102 million (YoY +9.3%)
Operating profit¥904 million (YoY +10.7%)
Ordinary income¥843 million (YoY +8.7%)
Net income¥631 million (YoY +25.8%)
Revision to Earnings ForecastNo revision
Annual Dividend Forecast¥20 → ¥20（0.0%）
Factors Behind Changes in Business Performance
New openings and an increase in the number of home-care patients in the Home-Visit Pharmacy business; expansion of consulting services and an increase in the number of member companies and member stores through seminars in the Kirari Prime business; and improved occupancy rates and average resident spending at certain facilities in the Primary Care Home business.
Disclosure regarding the going concern assumption
No applicable matters
Change in accounting policy
基準改正に伴う変更 Noそれ以外の変更 No見積りの変更 No修正再表示 No
Changes in the scope of consolidationNew Number of companies 0 / Company name Not disclosed / Excluded Number of companies 0 / Company name Not disclosed
Impairment loss¥0 thousand
Breakdown of extraordinary income (loss)Extraordinary income Gain on business transfer ¥3,556 thousand / Extraordinary loss No recognition
Depreciation and amortization¥87,978 thousand
Availability of Supplementary Financial Results MaterialsYes
Availability of Financial Results BriefingNone (対象者：Not applicable)
Issued Shares at Period-End7,279,000
Treasury Shares at Period-End147,128
| Item | Details |
|---|---|
| Fiscal Period Classification | First quarter |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 April 2026 to 30 June 2026 |
| Net Sales | ¥3,287 million (YoY +27.1%) |
| Operating profit | ¥277 million (YoY +162.9%) |
| Ordinary income | ¥263 million (YoY +173.3%) |
| Profit attributable to owners of the parent | ¥176 million (YoY +176.9%) |
| Net income per share | ¥24.82 |
| Equity ratio | End of the current fiscal period 31.9 / End of previous period 32.9 |
| Total assets | ¥8,669 million |
| Net assets | ¥2,765 million |
| Full-year earnings forecast | Net Sales ¥13,102 million (YoY +9.3%) / Operating profit ¥904 million (YoY +10.7%) / Ordinary income ¥843 million (YoY +8.7%) / Net income ¥631 million (YoY +25.8%) |
| Revision to Earnings Forecast | No revision |
| Annual Dividend Forecast | ¥20 → ¥20（0.0%） |
| Segment revenue | Home-visit pharmacy business ¥2,298,441 thousand (YoY +24.5%), Kirari Prime Business ¥310,277 thousand (YoY +19.6%), Primary Care Home business ¥678,480 thousand (YoY +41.2%), Other businesses ¥111 thousand (YoY -40.2%) |
| Segment profit | Home-visit pharmacy business ¥179,687 thousand (YoY +13.7%), Kirari Prime Business ¥182,981 thousand (YoY +37.8%), Primary Care Home business ¥69,321 thousand, Other businesses ¥-7,226 thousand |
| Depreciation and amortization | ¥87,978 thousand |
| Impairment loss | ¥0 thousand |
| Breakdown of extraordinary income (loss) | Extraordinary income Gain on business transfer ¥3,556 thousand / Extraordinary loss No recognition |
| Disclosure regarding the going concern assumption | No applicable matters |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No |
| Changes in the scope of consolidation | New Number of companies 0 / Company name Not disclosed / Excluded Number of companies 0 / Company name Not disclosed |
| Availability of Supplementary Financial Results Materials | Yes |
| Availability of Financial Results Briefing | None (対象者：Not applicable) |
| Issued Shares at Period-End | 7,279,000 |
| Treasury Shares at Period-End | 147,128 |
| Factors Behind Changes in Business Performance | New openings and an increase in the number of home-care patients in the Home-Visit Pharmacy business; expansion of consulting services and an increase in the number of member companies and member stores through seminars in the Kirari Prime business; and improved occupancy rates and average resident spending at certain facilities in the Primary Care Home business. |
Items this document does not state (10)
Operating MarginCash flows from operating activitiesCash flows from investing activitiesCash flows from financing activitiesCash and cash equivalents at end of periodPayout ratioShareholder Return PolicyRegional salesOrders received and order backlogMaterial subsequent events
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The factors cited include new openings and an increase in the number of home-care patients in the Home-Visit Pharmacy business; expansion of consulting services and an increase in the number of member companies and member stores driven by seminars in the Kirari Prime business; and improved occupancy rates and average resident spending at certain facilities in the Primary Care Home business.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.